Targeting IL-22RA1 with Temtokibart: A Novel Approach in Atopic Dermatitis: Phase 2a Monotherapy Study Results

Journal:

The Journal of Allergy and Clinical Immunology

Published:

2025-11-14

DOI:

10.1016/j.jaci.2025.08.034

Affiliations:

10

Authors:

13

Go to article

Institutions	Authors	Share
LEO Pharma A/S, Denmark	6.000000	0.46
University of Lübeck, Germany	1.000000	0.08
AllerVie Health – Homewood, United States of America (USA)	1.000000	0.08
University of Rzeszów, Poland	1.000000	0.08
First OC Dermatology, United States of America (USA)	1.000000	0.08
Lynderm Research Inc., Canada	1.000000	0.08
Charité - University Medicine Berlin, Germany	1.000000	0.08
Queen's University, Canada	0.500000	0.04
Probity Medical Research Inc. (PMR), Canada	0.500000	0.04

Interested in Clinical Sciences?